Redefining Clinical Benefit in Leber Hereditary Optic Neuropathy: An Integrated Analysis of RHODOS and LEROS Studies Supports a Novel Efficacy Endpoint (ARVO 2026) - May 8, 2026 - Abstract #3125 - 0526; Pres time: May 5, 2026; 01:15 PM - 03:00 PM; Location: Poster Hall; Exhibit Hall; Posterboard Number: 0526; "CRB considers any stabilization or worsening of best BCVA that remains below a threshold for severe impairment as a beneficial outcome, whereas OB defines any stabilization or clinically non-relevant worsening (<0.2 logMAR) within the on-chart range as beneficial. Further investigation is warranted to understand the clinical implications of these differing criteria."
Clinical • Inherited Retinal Dystrophy • Ocular Inflammation • Ophthalmology • Optic Neuritis
|
|
Nancy Newman1; Patrick Yu-Wai-Man2,3; Alfredo A. Sadun4; Valerio Carelli5,6; Rod Gossen7; Daniela Garavaglia8; Karen Sison Lance7; Caroline Fradette7; Xavier Llòria8; Thomas Klopstock9,10
|